Diazepam (Valtoco) vs Lorazepam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valtoco)
Marketed by Neurelis, Inc.
NCT02721069 · Phase 3 · completed
The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.
Next expected readout: December 2026 · NCT06346262 (registry estimate)
Reported efficacy
Number of Participants Who Received NRL-1 (Valtoco) (12 months): Number of Participants Who Received NRL-1 (Valtoco) (12 months): NRL-1 5mg 9 Participants | NRL-1 10mg 54 Participants | NRL-1 15 mg 46 Participants | NRL-1 20mg 54 Participants (not_applicable)
Result source: NCT02721069
Lorazepam
Marketed by Hikma Pharmaceuticals PLC
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Diazepam (Valtoco) | Lorazepam |
|---|---|---|
| Seizure frequency, % change | —Not reported | —Not posted · NCT00004297 |
| 50% responder rate | —Not reported | —Not posted · NCT00004297 |
| Seizure freedom | —Not reported | —Not posted · NCT00004297 |
Seizure frequency, % change
- Diazepam (Valtoco)
- —Not reported
- Lorazepam
- —Not posted · NCT00004297
50% responder rate
- Diazepam (Valtoco)
- —Not reported
- Lorazepam
- —Not posted · NCT00004297
Seizure freedom
- Diazepam (Valtoco)
- —Not reported
- Lorazepam
- —Not posted · NCT00004297
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lorazepam: registry results are on file for Epilepsy, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Diazepam (Valtoco): 3 of 4 rows · Lorazepam: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diazepam (Valtoco) |
|---|---|
| Dropout rate | —20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results—15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 5.3% NCT02724423 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results—15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 —5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 — NCT02724423 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 24.1%20mga NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results32.6%15mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 37%10mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 22.2%5mg NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 1.8% NCT02724423 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 20mga nasal discomfort 11.1% nasopharyngitis 7.4% upper respiratory tract infection 7.4% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 show 4 more results15mg seizure 15.2% upper respiratory tract infection 15.2% nasal discomfort 8.7% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 10mg nasopharyngitis 22.2% pyrexia 18.5% upper respiratory tract infection 16.7% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 5mg influenza 33.3% diarrhoea 22.2% nasopharyngitis 11.1% NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3 dysgeusia 5.3% nasal discomfort 3.5% nasopharyngitis 3.5% NCT02724423 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Lorazepam's landscape